EGFR and lung carcinoma: Since the aberrant activation of STAT3 was found to be related to EGFR-TKI resistance in lung cancer, some natural compounds were proved to successfully reduce cell growth and induce apoptosis in EGFR-TKI-resistant NSCLC cells through the suppression of STAT3 activity, showing their potential as novel therapeutics for lung cancer patients with EGFR-TKI resistance [47].